Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05172726 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

StatusActive, Not Recruiting
PhasePhase 3
Started2021-12-02
View on ClinicalTrials.gov ↗

Amendment history

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
2026-04-16
2 amendments v9-v10
2 re-verifications since 2025-12-11, no change to tracked fields
2025-11-04
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v8
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2026-09→2026-10
Completion date2026-09→2026-10
Enrollment targetestimated 100→confirmed 58
Study sitesdetails revised at 19 of 19 sites
2025-10-10
Study Status, Contacts/Locations v7
Study sites19 entries, revised
Northwest Arkansas Clinical SiteTrials Center, PLLC First OC Dermatology Mission Dermatology Center RM Medical Research San Marcus Research Clinic, Inc. Olympian Clinical SiteResearch Northwestern University Feinberg School of Medicine Dawes Fretzin Clinical SiteResearch Group ClinicalOptions SiteResearch Group ClinicalWright SiteState Physicians Pharmacology Translational Unit ClinicalOregon SiteDermatology & Research Center ClinicalDermatology SiteSpecialists of Spokane ClinicalDermatology SiteResearch Institute Inc. ClinicalRejuvenation SiteLaser Dermatology Clinics ClinicalSkincare SiteStu [...] [...]
2025-05-30
Study Identification, Study Status, Sponsor/Collaborators, Contacts/Locations, IPDSharing v6
Lead sponsorDermavant Sciences, Inc.→Organon and Co
Study sites19 entries, revised
Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Site Dermavant Clinical Trials Dermavant Clinical Site Dermavant Clinical Site
2024-12-05
Study Status v5
Primary completion date2026-05→2026-09
Completion date2026-06→2026-09
Show 3 earlier versions
2023-09-07
Study Status, Contacts/Locations, References v4
Primary completion date2023-12→2026-05
Completion date2023-12→2026-06
Study sites11→19
Publications20 to 1 entries
Cappon GD and Hurtt ME. Developmental toxicity of the kidney. In: Kapp RW and Yyl L, editors. Reproductive Toxicology, Target Organ Series, 3rd edition. New York:Informa Healthcare, 2010:;93-204. Frazier KS and Seely JC. Urinary system. In: Sahota PS, Popp JA, Hardisty JF and Gopinath C, editors. To [...]
2023-03-24
Study Status v3
Re-verified, no change to tracked fields
2022-02-23
Study Status, Contacts/Locations v2
Study sites4→11
2021-12-10
Original filing
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
Trial Details
NCT Number NCT05172726
Lead Sponsor Organon and Co
Conditions Plaque Psoriasis
Enrollment 58 participants
Start Date 2021-12-02
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-17